Advertisement

Fettstoffwechselstörungen

  • E. Windler
  • H. Greten

Zusammenfassung

Fettstoffwechselstörungen sind ätiologisch und pathogenetisch uneinheitlich. Sie zeichnen sich durch Erhöhung oder Erniedrigung einer oder mehrerer der 4 Klassen der Plasmalipoproteine aus: Chylomikronen, Very low density Lip oproteine (VLDL), Low density Lipoproteine (LDL) und High density Lipoproteine (HDL) [14, 16, 18].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Assmann G (1993) Lipid Metabolism Disorders and Coronary Heart Disease. MMV Medizin Verlag, MünchenGoogle Scholar
  2. 2.
    Cremer P, Nagel D, Lâbrot B, Muche R, Elster H, Mann H, Seidel D (1991) Göttinger Risiko-, Inzidenz-und Prävalenzstudie (GRIPS). Springer Verlag, Heidelberg Berlin New York TokyoCrossRefGoogle Scholar
  3. 3.
    Greten H, Rieger H, Sinzinger H, Standl E, Windier E (1998) Arteriosklerose. In: Rieger H, Schoop H (Hrsg): Klinische Angiologie. Springer Verlag, Heidelberg, S 34–74Google Scholar
  4. 4.
    Haenszel W, Kurihara M (1968) Studies of japanese migrants. I. Mortality from cancer and other diseases among japanese in the united states. J Natl Cancer Institute 40: 43–68Google Scholar
  5. 5.
    Kannel WB (1983) High-density lipoproteins: Epidemiologic profile and risks of coronary artery disease. Amer J Cardiol 52:9b -12bGoogle Scholar
  6. 6.
    Kannel WB, Neaton JD, Wentworth D, Thomas HE, Stamler J, Hulley SB, Kjelsberg MO (1986) Overall and coronary heart disease mortality rates in relation to major risk factors in 325 348 men screened for the MRFIT. Am Heart J 112:825-836PubMedCrossRefGoogle Scholar
  7. 7.
    Keys A, Menotti A, Aravanis C, Blackburn H, Djordevic BS, Buzina R, Dontas AS, Fidanza F, Karvonen MJ, Kimura N Mohacek I, Nedeljkovic S, Puddu V, Punsar S, Taylor HL, Conti S, Kromhout D, Toshima H (1984) The seven countries study: 2.289 deaths in 15 Years. Preventive Med 13: 141–154CrossRefGoogle Scholar
  8. 8.
    Löwel H, Lewis M, Keil U, Hörmann A, Bolte H-D, Willich S, Gostomzyk J (1995) Zeitliche Trends von Herzinfarktmorbidität, -mortalität, 28-Tage-Letalität und medizinischer Versorgung. Z Kardiol 84 : 596–605PubMedGoogle Scholar
  9. 9.
    National Cholesterol Education Program (1994) Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Circulation 89:1333–1445Google Scholar
  10. 10.
    Ornish D, Brown SE, Scheerwitz LW, Billings JH, Armstrong WT, Ports TA, McLanahan SM, Kirkeeide RL, Brand RJ, Gould KL (1990) Can lifestyle changes reverse coronary heart disease?–The Lifestyle Heart Trial. Lancet 336: 129–133PubMedCrossRefGoogle Scholar
  11. 11.
    Pedersen TR, Olsson AG, Færgeman O, Berg K, Miettinen T, Wedel H for the 4S Group (1995) Simvastatin-induced Reduction in Risk of Major Coronary Events is Related to Both Reduction in LDL-Cholesterol and Increase in HDLCholesterol. Circulation 92:I -198Google Scholar
  12. 12.
    Pyörälä K, DeBacker G, Graham I, Poole-Wilson P, Wood D on behalf of the Task Force (1994) Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis 110: 121–161PubMedCrossRefGoogle Scholar
  13. 13.
    Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383–1389Google Scholar
  14. 14.
    Schwandt P, Richter WO (1995) Handbuch der Fettstoffwechselstprungen. Schattauer Verlag, StuttgartGoogle Scholar
  15. 15.
    Shepherd J, Cobbe SM, Ford I, Isles CH, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group (1995) Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia. N Engl J Med 333: 1301–1307PubMedCrossRefGoogle Scholar
  16. 16.
    Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS (1983) The Metabolic Basis of Inherited Diseases, 5. Ausgabe Part 4, Disorders of Lipoprotein and Lipid Metabolism, S 589–750Google Scholar
  17. 17.
    Steinberg D (1993) Modified forms of low-density lipoprotein and atherosclerosis. J Intern Med 233:227–32CrossRefGoogle Scholar
  18. 18.
    Thompson GR (1990) A Handbook of Hyperlipidaemia. London: Current ScienceGoogle Scholar
  19. 19.
    Watts, GF, Jackson, P, Mandalia, S, Brunt, JN, Lewis, ES, Coltart, D J, Lewis, B (1994) Nutrient intake and progression of coronary artery disease. Amer J Cardiol 73: 328–32PubMedCrossRefGoogle Scholar
  20. 20.
    Windler E (1997) Lipidtherapie in der Prävention und Behandlung koronarer Herzkrankheiten. HamburgGoogle Scholar
  21. 21.
    Windler E (1998) Hyper-und Dyslipoproteinämien. In: Wolff HP, Weihrauch TR (Hrsg) Internistische Therapie 98/99. 12. Aufl., Urban & Schwarzenberg, München S 989–1014Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • E. Windler
  • H. Greten

There are no affiliations available

Personalised recommendations